Receptor tyrosine kinase signalling pathways have been successfully targeted to inhibit
proliferation and angiogenesis for cancer therapy. However, kinase deregulation has been …

In contrast to the multiple disease-modifying therapies that are available for relapsing–
remitting multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) are …

Background Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase,
may increase platelet counts in patients with immune thrombocytopenia by means of dual …

Pemphigus encompasses a heterogeneous group of autoimmune blistering diseases, which
affect both mucous membranes and the skin. The disease usually runs a chronic-relapsing …

Bruton's tyrosine kinase (BTK) is a TEC kinase with a multifaceted role in B‐cell biology and
function, highlighted by its position as a critical component of the B‐cell receptor signalling …

The covalent Bruton tyrosine kinase (BTK) inhibitor ibrutinib is highly efficacious against
multiple B-cell malignancies. However, it is not selective for BTK, and multiple mechanisms …

Bruton tyrosine kinase (BTK) is expressed in B cells and innate immune cells, acting as an
essential signaling element in multiple immune cell pathways. Selective BTK inhibition has …

Our pathophysiological concept of the most common central nervous system demyelinating
disease, multiple sclerosis, strikingly evolved by recent discoveries suggesting that B …

Bruton's tyrosine kinase (BTK), a member of the Tec kinase family, is critically involved in a
range of immunological pathways. The clinical application of BTK inhibitors for B‐cell …

Bruton's tyrosine kinase (BTK), a Tec family tyrosine kinase, is critical in immune pathways
as an essential intracellular signaling element, participating in both adaptive and immune …